Predict your next investment

Asset/Investment Management

See what CB Insights has to offer

Investments

89

Portfolio Exits

36

About SDS Capital Partners

SDS Capital Partners is a Connecticut-based financial advisory firm that invests in PIPEs and private companies.

SDS Capital Partners Headquarter Location

53 Forest Avenue #201

Old Greenwich, Connecticut, 06870-1537,

United States

203-637-000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest SDS Capital Partners News

Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement to Fund Initiation of the First Phase 3 Celiac Disease Clinical Trial

Mar 18, 2019

| Source: Innovate Biopharmaceuticals, Inc RALEIGH, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate” or the “Company”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that on March 17, 2019, it entered into an agreement (the “Agreement”) with SDS Capital Partners II LLC and certain other accredited investors (together, the “Purchasers”) providing for the sale by the Company at a purchase price of $2.33 per share as further described below of up to 4,291,845 shares (the “Shares”) of its common stock (the “Common Stock”), up to 2,575,107 five-year term warrants with an exercise price as further described below at a premium to the purchase price and up to 4,291,845 12-month term warrants at an exercise price of $4.00 (total of up to 6,866,952 shares of Common Stock). The Company intends to use the net proceeds from this offering to fund initiation of the first Phase 3 clinical trial of its lead program for celiac disease, INN-202, and for working capital and general corporate purposes. The 12 month warrants will be immediately exercisable at a price of $4.00 per share for one year, and the five year warrants will be exercisable beginning on the six month anniversary of their issuance at a price equal to the greater of (a) 125% of the volume weighted average price of the Common Stock for the 20 day period prior to the closing date of the private placement and (b) the closing price of the Common Stock immediately prior to the closing date of the private placement. If the volume weighted average price of our stock exceeds $5.25 for 10 consecutive days following their issue dates, we will have the right to call the 12 month warrants for cash exercise. The exercise prices of the warrants will be subject to adjustment for, among other things, stock splits, reverse splits, and similar capital transactions, and the warrant holders will have certain rights on an as-exercised basis as holders of Common Stock in the event of certain distributions and fundamental transactions. The warrants will be exercisable on a “cashless” basis only in certain circumstances. The Agreement contains customary representations, warranties, covenants, closing conditions and indemnification obligations. The Agreement contains a 45 day prohibition on certain sales or issuances of Common Stock or securities convertible or exchangeable into Common Stock without the prior written consent of the Purchasers, subject to certain exceptions. The Company has agreed to file a registration statement for resale of the shares underlying the warrants within 60 days of the date of the Agreement. The Shares are being issued pursuant to the Company’s shelf registration statement declared effective by the Securities and Exchange Commission on July 13, 2018 and a prospectus supplement dated March 17, 2019 to the registration statement. The issuance of the warrants is being made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended, for the offer and sale of securities not involving a public offering and Regulation D promulgated thereunder. The closing of the sale of the Shares and the concurrent private placement of warrants is expected to occur on March 18, 2018. There can be no assurance that we will close the offering or the private placement, or with the respect to the amount of proceeds to be received therefrom. About Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT): Innovate is a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases. Innovate’s lead drug candidate, larazotide acetate, has a mechanism of action that renormalizes the dysfunctional intestinal barrier by decreasing intestinal permeability and reducing antigen trafficking, such as gliadin fragments in celiac disease, and bacterial toxins and immunogenic antigens in nonalcoholic steatohepatitis (NASH). In several diseases, including celiac disease, NASH, Crohn’s disease, ulcerative colitis, irritable bowel syndrome (IBS), type 1 diabetes mellitus (T1DM), chronic kidney disease (CKD), the intestinal barrier is dysfunctional with increased permeability. Forward Looking Statements This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations, business strategy, corporate updates and capital raising activities. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, as well as the risks that prior clinical and preclinical results may not be replicated. These risks and uncertainties include, but may not be limited to, those described in our Quarterly Report on Form 10-Q filed with the SEC on November 13, 2018, and in any subsequent filings with the SEC. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law. SOURCE: Innovate Biopharmaceuticals, Inc.

SDS Capital Partners Investments

89 Investments

SDS Capital Partners has made 89 investments. Their latest investment was in 9 Meters Biopharma as part of their PIPE on March 3, 2019.

CBI Logo

SDS Capital Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/20/2019

PIPE

9 Meters Biopharma

$9.7M

Yes

1

12/19/2018

Unattributed - V

IliAD Biotechnologies

$12.8M

Yes

1

7/13/2007

PIPE - IV

Buy Kratom Bulk USA

$8.42M

No

3/16/2007

PIPE

Subscribe to see more

$99M

Subscribe to see more

0

1/5/2007

Unattributed VC - V

Subscribe to see more

$99M

Subscribe to see more

0

Date

3/20/2019

12/19/2018

7/13/2007

3/16/2007

1/5/2007

Round

PIPE

Unattributed - V

PIPE - IV

PIPE

Unattributed VC - V

Company

9 Meters Biopharma

IliAD Biotechnologies

Buy Kratom Bulk USA

Subscribe to see more

Subscribe to see more

Amount

$9.7M

$12.8M

$8.42M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

0

0

SDS Capital Partners Portfolio Exits

36 Portfolio Exits

SDS Capital Partners has 36 portfolio exits. Their latest portfolio exit was AMAG Pharmaceuticals on November 16, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/16/2020

Acq - P2P

$99M

3

6/21/2012

Acquired

12/16/2011

Acq - P2P

1

3/3/2011

IPO

Subscribe to see more

Subscribe to see more

10

10/17/2008

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

11/16/2020

6/21/2012

12/16/2011

3/3/2011

10/17/2008

Exit

Acq - P2P

Acquired

Acq - P2P

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

1

10

0

SDS Capital Partners Acquisitions

2 Acquisitions

SDS Capital Partners acquired 2 companies. Their latest acquisition was Rainmaker Systems on May 17, 2004.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/17/2004

Other Venture Capital

$99M

$16.7M

Acquired

1/24/2003

Private Equity

Subscribe to see more

$99M

$99M

Subscribe to see more

0

Date

5/17/2004

1/24/2003

Investment Stage

Other Venture Capital

Private Equity

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$16.7M

$99M

Note

Acquired

Subscribe to see more

Sources

0

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.